Posted on

In case it’s not clear, hear at the Daily Leaf, we support access to marijuana for medical purposes. But we do think that it’s unfortunate that due to limitations on the research that can be conducted using marijuana in America, there’s very little rigor in how the substance is prescribed. Putting aside the fact that the medical establishment knows next to nothing about the varied effects of the many non THC cannabinoids within the plant, there is no other medication that doctors give a patient a license to consume without clear guidelines regarding appropriate dosage and timing. Recently, however, an Israeli team produced 3D printed weed inhalers that will allow doctors to control the timing and dosage of cannabis administered to a patient.

As reported in Quartz, researchers at Israel-based Syqe Medical have developed a product that is capable of delivering a precise cannabis dosage through inhalation. The start-up’s cannabis inhaler has been approved by the Israeli Ministry of Health and has already been in use on a trial basis Haifa’s Rambam Hospital, where marijuana forms a standard part of many treatments. Syqe Medical has teamed up with Teva Pharmaceuticals, one of the largest generic drug manufacturers in the world, to manufacture and distribute the device.

Currently, most medical marijuana users in Israel smoke their cannabis. Doctors prefer this device because it allows patients to consume cannabinoids without involving combustion, thereby eliminating or reducing exposure to carcinogens. The broader implications of the technology may be wider, however. The device administers a controlled dose and one version of it allows doctors to control the timing of the dose, it may pave the way for better controlled and more finely tuned research on the medical applications of marijuana.
As of now, there’s no word on plans for the international distribution of the device. For the product to be even semi-legally sold on American shores, manufacturing would likely have to be decentralized within the states where the inhaler would be sold. But because the device is 3D printer, licensing its design may prove easy to scale.